6533b839fe1ef96bd12a65b8
RESEARCH PRODUCT
SLIT's Prevention of the Allergic March.
Giovanni Battista PajnoFederica PorcaroGiovanni Corsellosubject
Allergic march0301 basic medicinePulmonary and Respiratory MedicineAllergen immunotherapymedicine.medical_specialtyAllergyImmunologyDiseaseSublingual administration03 medical and health sciences0302 clinical medicineAllergen immunotherapy; Allergic march; Primary prevention; Secondary prevention; Sublingual immunotherapy; Immunology and Allergy; Immunology; Pulmonary and Respiratory MedicinemedicineHypersensitivityImmunology and AllergyHumansAllergen immunotherapyAsthmaSecondary preventionSublingual ImmunotherapyPrimary preventionbusiness.industrySecondary preventionAtopic dermatitismedicine.diseaseDermatologySlit030104 developmental biology030228 respiratory systembusinessdescription
PURPOSE OF REVIEW: The progression of atopic disorders from atopic dermatitis in infants to allergic rhinitis and asthma in children, adolescents, and adults defines the allergy march. Allergen immunotherapy is the only causal treatment altering the immunological mechanism underlying the allergic diseases. The sublingual administration route is more acceptable than the subcutaneous one in pediatric age. RECENT FINDINGS: Several studies show the efficacy and safety profile of sublingual immunotherapy (SLIT) for the treatment of respiratory allergy diseases, but few data are available on its effect of primary and secondary prevention of allergic disease. The purpose of this manuscript is to review the latest studies addressing the effect of SLIT on the development of new sensitizations in not sensitized or already sensitized patients and progression of the allergy march.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2018-01-01 | Current allergy and asthma reports |